Advertisement
News
Advertisement

Idera stock drops on hepatitis-C drug delay

Tue, 04/26/2011 - 6:35am
Mass High Tech: The Journal of New England Technology

Idera Pharmaceuticals Inc.’s (Nasdaq: IDRA) stock dropped more than 5 percent Monday, following the company’s announcement that it would delay the launch of a clinical trial on its drug candidate for hepatitis C, due to toxicology study results on rodents that showed instances of atypical proliferation of a type of white blood cells, called lymphocytes. High levels of lymphocytes are generally associated with viral infections.

The company announced its decision on Friday, when the markets were closed.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading